Reference : Intermittent Versus Continuous Total Androgen Blockade in the Treatment of Patients w...
Scientific journals : Article
Human health sciences : Urology & nephrology
http://hdl.handle.net/2268/36252
Intermittent Versus Continuous Total Androgen Blockade in the Treatment of Patients with Advanced Hormone-Naive Prostate Cancer: Results of a Prospective Randomized Multicenter Trial
English
De Leval, Jean mailto [Centre Hospitalier Universitaire de Liège - CHU > > Urologie >]
Boca, Philippe [Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > > > > > >]
Yousef, Enis [CHU Sousse Tunisie > > > > > >]
Nicolas, Hubert [Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > > > > > >]
Jeukenne, Michel [CHU NDB > > > > > >]
Seidel, Laurence mailto [Université de Liège - ULg > Département des sciences de la santé publique > Informatique médicale et biostatistique >]
Bouffioux, Christian mailto [Université de Liège - ULg > Département des sciences de la santé publique > Gestion et législation hospitalières]
Coppens, Luc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Urologie >]
Bonnet, Pierre mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie humaine systématique >]
Andrianne, Robert [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques]
Waltregny, David mailto [Université de Liège - ULg > Département des sciences cliniques > Urologie - GIGA-R : Labo de recherche sur les métastases >]
Dec-2002
Clinical Prostate Cancer
1
3
163-71
Yes (verified by ORBi)
International
1540-0352
[en] prostate cancer ; androgen deprivation ; intermittent
[en] The aim of this study was to compare the efficacy of total intermittent androgen deprivation (IAD) versus total continuous androgen deprivation (CAD) for treating patients with advanced prostate cancer in a phase III randomized trial. A total of 68 evaluable patients with hormone-naive advanced or relapsing prostate cancer were randomized to receive combined androgen blockade according to a continuous (n = 33) or intermittent (n = 35) regimen. Therapeutic monitoring was assessed by use of serum prostate-specific antigen (PSA) measurements. Patients in the CAD and IAD groups were equally stratified for age, biopsy Gleason score, and baseline serum PSA levels. The outcome variable was time to androgen-independence of the tumor, which was defined as increasing serum PSA levels despite androgen blockade. Mean follow-up was 30.8 months. The 35 IAD-treated patients completed 91 cycles, and 19 of them (54.3%) completed > or = 3 cycles. Median cycle length and percentage of time off therapy were 9.0 months and 59.5, respectively. The estimated 3-year progression rate was significantly lower in the IAD group (7.0% +/- 4.8%) than in the CAD group (38.9% +/- 11.2%, P = 0.0052). Our data suggest that IAD treatment may maintain the androgen-dependent state of advanced human prostate cancer, as assessed by PSA measurements, at least as long as CAD treatment. Further studies with longer follow-up times and larger patient cohorts are needed to determine the comparative impacts of CAD and IAD on survival.
Researchers ; Professionals
http://hdl.handle.net/2268/36252
also: http://hdl.handle.net/2268/4721

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Intermittent.pdfPublisher postprint156.19 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.